Nektar Therapeutics (LTS:0UNL) Short Interest


LTS:0UNL Nektar Therapeutics LTS:0UNL
49 GF Score
Price $61.67
GF Value $5.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0UNL vs PHVS, KOD, RARE: Short Interest Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Short Interest falls into.


LTS:0UNL
49GF Score
Nektar Therapeutics LTS:0UNL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nektar Therapeutics (LTS:0UNL) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of $61.67 is trading 961.4% above its estimated GF Value™ of $5.81. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0UNL:

  • Short Interest:
  • GF Value™: $5.81 vs. price of $61.67 (961.4% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the LTS:0UNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USAITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
49GF Score

Get the complete analysis for LTS:0UNL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.67
Price
$5.81
GF Value